165 related articles for article (PubMed ID: 32600694)
21. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
[TBL] [Abstract][Full Text] [Related]
22. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial.
Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; Otaegui I; Masotti M; Zueco J; Veláquez M; Sanchís J; García-Touchard A; Lázaro-García R; Moreu J; Bethencourt A; Cuesta J; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
JACC Cardiovasc Interv; 2016 Jun; 9(12):1246-1255. PubMed ID: 27339840
[TBL] [Abstract][Full Text] [Related]
24. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of promoting effect of a novel Cu-bearing metal stent on endothelialization process from in vitro and in vivo studies.
Jin S; Qi X; Zhang B; Sun Z; Zhang B; Yang H; Wang T; Zheng B; Wang X; Shi Q; Chen M; Ren L; Yang K; Zhong H
Sci Rep; 2017 Dec; 7(1):17394. PubMed ID: 29234061
[TBL] [Abstract][Full Text] [Related]
26. Drug-Eluting Stent Targeting Sp-1-Attenuated Restenosis by Engaging YAP-Mediated Vascular Smooth Muscle Cell Phenotypic Modulation.
Huang C; Zhao J; Zhu Y
J Am Heart Assoc; 2020 Jan; 9(1):e014103. PubMed ID: 31880978
[TBL] [Abstract][Full Text] [Related]
27. Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents.
Steinberg DH; Gaglia MA; Pinto Slottow TL; Roy P; Bonello L; De Labriolle A; Lemesle G; Torguson R; Kineshige K; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2009 Feb; 103(4):491-5. PubMed ID: 19195508
[TBL] [Abstract][Full Text] [Related]
28. Chrysanthemum boreale flower floral water inhibits platelet-derived growth factor-stimulated migration and proliferation in vascular smooth muscle cells.
Kim DY; Won KJ; Yoon MS; Yu HJ; Park JH; Kim B; Lee HM
Pharm Biol; 2015 May; 53(5):725-34. PubMed ID: 25330930
[TBL] [Abstract][Full Text] [Related]
29. Effect of alpha lipoic acid in a porcine in-stent restenosis model.
Lim SY; Bae EH; Jeong MH; Kim JH; Hong YJ; Sim DS; Kim YS; Park IK; Ahn Y; Song SJ; Cho DL; Kim KS; Kang JC
J Cardiol; 2009 Dec; 54(3):375-85. PubMed ID: 19944312
[TBL] [Abstract][Full Text] [Related]
30. Osteoprotegerin promotes intimal hyperplasia and contributes to in-stent restenosis: Role of an αVβ3/FAK dependent YAP pathway.
He Y; Zou P; Lu Y; Jia D; Li X; Yang H; Tang L; Zhu Z; Tu T; Tai S; Xiao Y; Chen M; Lu L; Zhou S
J Mol Cell Cardiol; 2020 Feb; 139():1-13. PubMed ID: 31958462
[TBL] [Abstract][Full Text] [Related]
31. Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor α and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells.
Chieng-Yane P; Bocquet A; Létienne R; Bourbon T; Sablayrolles S; Perez M; Hatem SN; Lompré AM; Le Grand B; David-Dufilho M
J Pharmacol Exp Ther; 2011 Mar; 336(3):643-51. PubMed ID: 21139058
[TBL] [Abstract][Full Text] [Related]
32. Effect of a novel peptide, WKYMVm- and sirolimus-coated stent on re-endothelialization and anti-restenosis.
Jang EJ; Bae IH; Park DS; Lee SY; Lim KS; Park JK; Shim JW; Sim DS; Jeong MH
J Mater Sci Mater Med; 2015 Oct; 26(10):251. PubMed ID: 26438653
[TBL] [Abstract][Full Text] [Related]
33. Antirestenotic mechanisms of everolimus on human coronary artery smooth muscle cells: inhibition of human coronary artery smooth muscle cell proliferation, but not migration.
Lavigne MC; Grimsby JL; Eppihimer MJ
J Cardiovasc Pharmacol; 2012 Feb; 59(2):165-74. PubMed ID: 21983747
[TBL] [Abstract][Full Text] [Related]
34. Tangeretin, a citrus flavonoid, inhibits PGDF-BB-induced proliferation and migration of aortic smooth muscle cells by blocking AKT activation.
Seo J; Lee HS; Ryoo S; Seo JH; Min BS; Lee JH
Eur J Pharmacol; 2011 Dec; 673(1-3):56-64. PubMed ID: 22040922
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
[TBL] [Abstract][Full Text] [Related]
36. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR
J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
Almalla M; Pross V; Marx N; Hoffmann R
Coron Artery Dis; 2012 Nov; 23(7):492-6. PubMed ID: 22990414
[TBL] [Abstract][Full Text] [Related]
38. The Role of Tauroursodeoxycholic Acid on Dedifferentiation of Vascular Smooth Muscle Cells by Modulation of Endoplasmic Reticulum Stress and as an Oral Drug Inhibiting In-Stent Restenosis.
Luo H; Zhou C; Chi J; Pan S; Lin H; Gao F; Ni T; Meng L; Zhang J; Jiang C; Ji Z; Lv H; Guo H
Cardiovasc Drugs Ther; 2019 Feb; 33(1):25-33. PubMed ID: 30663009
[TBL] [Abstract][Full Text] [Related]
39. In vitro study of role of trace amount of Cu release from Cu-bearing stainless steel targeting for reduction of in-stent restenosis.
Ren L; Xu L; Feng J; Zhang Y; Yang K
J Mater Sci Mater Med; 2012 May; 23(5):1235-45. PubMed ID: 22359212
[TBL] [Abstract][Full Text] [Related]
40. Bare metal stent implantation for in-stent restenosis with a drug-eluting stent.
Matsuoka H; Kawakami H; Ohshita A; Kohno T; Shigemi S; Okayama H; Higaki J
J Cardiol; 2010 Jan; 55(1):135-8. PubMed ID: 20122561
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
